Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Magnetic Nanoworms and Nanocrystals Deliver siRNA to Tumors

Abstract:
Small pieces of nucleic acid known as short interfering RNAs, or siRNAs, can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials.

Magnetic Nanoworms and Nanocrystals Deliver siRNA to Tumors

Bethesda , MD | Posted on September 23rd, 2009

Now, investigators at the Massachusetts Institute of Technology (MIT) have developed a modular nanoparticle-based drug delivery system that maximizes the quantity of siRNA molecules that not only can enter cells but also can escape into the cytoplasm, where they can interfere with protein production. Sangeeta Bhatia, M.D., Ph.D., and Phillip A. Sharp, Ph.D., of the MIT-Harvard Center of Cancer Nanotechnology Excellence, and Alain Charest, Ph.D., M.Sc., Tufts University School of Medicine, led the study, whose results appear in the journal ACS Nano.

The new siRNA delivery vehicle is made of dendrimer-conjugated magnetic and fluorescent nanoworms that the investigators call "dendriworms." Dendrimers are synthetic polymers that generally have a spherical shape and that can be readily modified to carry a wide range of molecules, including nucleic acids. In this work, Dr. Bhatia and her colleagues used polyamidoamine dendrimers, which a large body of preclinical work has shown are fully biocompatible, and coupled them to a chain of magnetic nanoparticles known as a nanoworm. The investigators also added a fluorescent molecule to the nanoworms, thereby creating a drug delivery vehicle that they could also image in the body using either magnetic resonance imaging or fluorescence imaging. In a final step, the researchers added siRNA to the dendriworms. The resulting construct, which contains approximately 7 magnetic nanoparticles, 45-50 dendrimers, and 50 siRNA molecules, was stable under test conditions for up to 6 hours.

When added to cells growing in culture, this siRNA-dendrimer complex rapidly entered the cells and then escaped into the cellular cytoplasm. The researchers observed no significant toxicity in these in vitro experiments. When the dendriworms were administered to human glioblastoma cells, the delivered siRNA was able to silence production of the targeted gene, in this case a mutant gene known to be involved in glioblastoma development.

To test whether this dendriworm would work in a living animal, the researchers used a strain of mice that were genetically engineered to develop glioblastoma tumors spontaneously in the brain. The investigators found that the dendriworms were able to penetrate the tumors, deliver their therapeutic siRNA cargo into tumor cells, and silence the targeted gene in those cells.

Meanwhile, a group of investigators at The Jikei University School of Medicine in Tokyo, Japan, led by Yoshihisa Namiki, M.D., has demonstrated that lipid-coated magnetic crystals can safely and effectively deliver therapeutic siRNA to tumors in mice. The results of their experiments were published in the journal Nature Nanotechnology.

Dr. Namiki and his colleagues created their delivery vehicle by coating iron oxide nanocrystals with a layer of positively charged lipids. This layer binds strongly to siRNA molecules, which— like all nucleic acids—have a strong negative charge. After optimizing the lipid coating to maximize siRNA delivery efficiency, the investigators used their nanoparticle to deliver an anti-EGFR siRNA to gastric tumors in mice. After injecting the mice with the therapeutic nanoparticles, the investigators applied a local magnetic field around the vicinity of the tumor. After 28 days, tumors in the treated mice were 50% smaller compared with tumors in mice treated with just the nanoparticle and no siRNA.

####

About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

Copyright © National Cancer Institute

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

View abstract - “Functional delivery of siRNA in mice using dendriworms.”

View abstract - “A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery.”

Related News Press

News and information

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Exotic insulator may hold clue to key mystery of modern physics: Johns Hopkins-led research shows material living between classical and quantum worlds December 8th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Discoveries

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Announcements

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project